Skip to main content
Midas Edge

GLYCOMIMETICS INC

For the period ended Dec 31, 2024. Filed Feb 13, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 13, 2025

CBIO$13.65+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Statements of Stockholders’ Equity

​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · Paid-In · ​ · Accumulated · ​ · Stockholders’
​ · ​ · Shares · ​ · Amount · ​ · Capital · ​ · Deficit · ​ · Equity
Balance at December 31, 202254,377,798​$54,378​$462,461,251​$(419,585,792)​$42,929,837
Issuance of common stock, net of issuance costs9,822,930​9,823​28,697,188​—​28,707,011
Issuance of common stock for services24,001​24​35,976​—​36,000
Exercise of options and vesting of restricted stock units169,015​169​116,328​—​116,497
Stock-based compensation​—​​​​​3,524,476​​​​​3,524,476
Net loss—​—​—​(36,899,420)​(36,899,420)
Balance at December 31, 202364,393,744​​64,394​​494,835,219​​(456,485,212)​​38,414,401
Issuance of common stock for services28,383​28​75,347​—​75,375
Exercise of options and vesting of restricted stock units61,831​62​5,336​—​5,398
Stock-based compensation—​—​4,697,546​—​4,697,546
Net loss—​—​—​(37,879,158)​(37,879,158)
Balance at December 31, 202464,483,958​$64,484​$499,613,448​$(494,364,370)​$5,313,562
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.